Trial of Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma (RETRO-WTS)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1/PHASE2

Total Enrollment

37 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-03-31

Study Completion Date

2020-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Local control rates in patients with retroperitoneal soft tissue sarcoma (RSTS) remain disappointing even after gross total resection, mainly because wide margins are not achievable in the majority of patients. In contrast to extremity sarcoma, postoperative radiation therapy (RT) has shown limited efficacy due to its limitations in achievable dose and coverage. Although Intraoperative Radiation Therapy (IORT) has been introduced in some centers to overcome these dose limitations and resulted in improved outcome, local failure rates are still high even if considerable treatment related toxicity is accepted. As postoperative administration of RT has some general disadvantages, neoadjuvant approaches could offer benefits in terms of dose escalation, target coverage and reduction of toxicity, especially if highly conformal techniques like intensity-modulated radiation therapy (IMRT) are considered.

Therefore the RETROWTS trials has been designed as a prospective, one armed, single center phase I/II study investigating a combination of neoadjuvant dose-escalated IMRT (50-56 Gy) followed by surgery and IORT (10-12 Gy) in patients with at least marginally resectable RSTS. The primary objective is the local control rate after five years. Secondary endpoints are progression-free and overall survival, acute and late toxicity, surgical resectability and patterns of failure. The aim of accrual is 37 patients in the per-protocol population.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Surgical Timing After Preoperative Hypofractionated Radiotherapy for Localized Extremity and Trunk Soft Tissue Sarcoma

NCT07265661

Soft Tissue Sarcoma of the Trunk and Extremities

NOT_YET_RECRUITING NA

Proton or Photon RT for Retroperitoneal Sarcomas

NCT01659203

Retroperitoneal Sarcoma

RECRUITING PHASE1/PHASE2

Immediate Radiotherapy or Observation After Surgery for Melanoma Involving Lymph Nodes

NCT00287196

Malignant Melanoma Lymph Node Disease

COMPLETED PHASE3

A Prospective Randomized Trial of Pre-Operative IMRT+Surgery Versus Surgery Alone For Primary Retroperitoneal Sarcoma

NCT00131898

Sarcoma

COMPLETED PHASE3

Shorter Course, Hypofractionated Pre-Surgery Radiation Therapy in Treating Patients With Localized, Resectable Soft Tissue Sarcoma of the Extremity of Superficial Trunk

NCT03819985

Resectable Soft Tissue Sarcoma Stage I Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 Stage IA Soft Tissue Sarcoma of the Trunk and Extremities AJCC v8 +5 more

ACTIVE_NOT_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Retroperitoneal Soft Tissue Sarcoma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Neoadjuvant Intensity-Modulated Radiation Therapy Followed by Surgery and Intraoperative Radiation Therapy in Resectable Retroperitoneal Soft Tissue Sarcoma

Group Type EXPERIMENTAL

Neoadjuvant intensity-modulated radiation therapy (IMRT)

Intervention Type RADIATION

neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy

intraoperative radiation therapy (IORT)

Intervention Type RADIATION

during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Neoadjuvant intensity-modulated radiation therapy (IMRT)

neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy

Intervention Type RADIATION

intraoperative radiation therapy (IORT)

during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease

Intervention Type RADIATION

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* written informed consent
* histologically confirmed, primary or locally recurrent soft tissue sarcoma of the retroperitoneal space
* judged as at least marginally resectable
* absence of distant metastases
* tumor size ≥ 5 cm

Exclusion Criteria

* missing written informed consent
* missing histological confirmation of soft tissue sarcoma
* Desmoid tumor (syn. aggressive fibromatosis)
* judged as gross incomplete or not resectable
* incomplete staging
* presence of distant metastases
* prior radiation therapy to the abdominal region
* participation in another clinical interventional study
* inflammatory bowel disease

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No